AgomAb Therapeutics NV - ADRs representing one common share

Potential pricing power is meaningful if the programs succeed. FSCD currently lacks approved pharmacologic therapies; a safe, effective oral that reduces strictures and procedures could justify premium specialty pricing. IPF is an orphan disease with historically high pricing tolerance if safety and efficacy are strong.

Organ‑restricted mechanisms may aid risk‑benefit positioning. That said, all pricing power here is latent and contingent on pivotal data and payer acceptance of novel endpoints in FSCD, so we cap the score at moderate.